New therapeutic agents for chronic hepatitis B. (Q38706158)

5 September 2017

New therapeutic agents for chronic hepatitis B. (English)

1 reference

5 September 2017

1 reference

Mayur Brahmania

1

1 reference

5 September 2017

Jordan Feld

series ordinal

2

1 reference

5 September 2017

Ambreen Arif

series ordinal

3

1 reference

5 September 2017

Harry L A Janssen

series ordinal

4

1 reference

5 September 2017

12 January 2016

1 reference

Lancet Infectious Diseases

5 September 2017

1 reference

5 September 2017

16

1 reference

5 September 2017

e10-21

1 reference

5 September 2017

2

1 reference

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

5 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

1 reference

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Impact of hepatitis B therapy on the long-term outcome of liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Hepatitis B viruses: reverse transcription a different way.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Hepatitis B virus biology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Molecular genesis of drug-resistant and vaccine-escape HBV mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Strategies to inhibit entry of HBV and HDV into hepatocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

1 reference

7 January 2021

Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Inhibition of hepatitis B virus expression and replication by RNA interference

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

A Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen Secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

HBV life cycle: entry and morphogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Role of transmembrane domains of hepatitis B virus small surface proteins in subviral-particle biogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Host factors involved in hepatitis B virus maturation, assembly, and egress.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The PD-1-PD-L pathway in immunological tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Restoring function in exhausted CD8 T cells during chronic viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Therapeutic vaccination and novel strategies to treat chronic HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

The optimized capsid gene of porcine circovirus type 2 expressed in yeast forms virus-like particles and elicits antibody responses in mice fed with recombinant yeast extracts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Uptake of various yeast genera by antigen-presenting cells and influence of subcellular antigen localization on the activation of ovalbumin-specific CD8 T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Role of B cells in antigen presentation of the hepatitis B core

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900436-3

7 January 2021

10.1016/S1473-3099(15)00436-3

Identifiers

DOI

1 reference

5 September 2017

1 reference